APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Gene-based Advanced Therapy Medical Product

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Gene-based Advanced Therapy Medical Product Market Analysis and Forecast 2026-2032

Report ID 17399457022 January 2026192 pages

Choose your research edition.

Industry ResearchGene-based Advanced Therapy Medical Product Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Gene-based Advanced Therapy Medical Product Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Gene-based Advanced Therapy Medical Product Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gene-based Advanced Therapy Medical Product Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Gene-based Advanced Therapy Medical Product Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Gene-based Advanced Therapy Medical Product market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Gene-based Advanced Therapy Medical Product is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Gene-based Advanced Therapy Medical Product is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Gene-based Advanced Therapy Medical Product is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Gene-based Advanced Therapy Medical Product is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Gene-based Advanced Therapy Medical Product include Novartis, Amgen, Sunway Biotech, Spark Therapeutics, SIBIONO, Sarepta Therapeutics, Orchard Therapeutics, Human Stem Cells Institute and Gilead Sciences, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Gene-based Advanced Therapy Medical Product, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Gene-based Advanced Therapy Medical Product, also provides the revenue of main regions and countries. Of the upcoming market potential for Gene-based Advanced Therapy Medical Product, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gene-based Advanced Therapy Medical Product revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Gene-based Advanced Therapy Medical Product market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Gene-based Advanced Therapy Medical Product revenue, projected growth trends, production technology, application and end-user industry.

Gene-based Advanced Therapy Medical Product Segment by Company

Novartis

Amgen

Sunway Biotech

Spark Therapeutics

SIBIONO

Sarepta Therapeutics

Orchard Therapeutics

Human Stem Cells Institute

Gilead Sciences

bluebird bio

Biogen

AnGes

Alnylam Pharmaceuticals

Akcea Therapeutics

Gene-based Advanced Therapy Medical Product Segment by Type

Viral Gene Delivery System

Non-viral Gene Delivery System

Gene-based Advanced Therapy Medical Product Segment by Application

Neurological Diseases

Cancer

Other

Gene-based Advanced Therapy Medical Product Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene-based Advanced Therapy Medical Product market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gene-based Advanced Therapy Medical Product and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene-based Advanced Therapy Medical Product.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Gene-based Advanced Therapy Medical Product in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Gene-based Advanced Therapy Medical Product company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gene-based Advanced Therapy Medical Product revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Gene-based Advanced Therapy Medical Product Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Viral Gene Delivery System Major Player Table 3. Non-viral Gene Delivery System Major Player Table 4. Global Gene-based Advanced Therapy Medical Product Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Neurological Diseases Major Player Table 6. Cancer Major Player Table 7. Other Major Player Table 8. Gene-based Advanced Therapy Medical Product Industry Trends Table 9. Gene-based Advanced Therapy Medical Product Industry Drivers Table 10. Gene-based Advanced Therapy Medical Product Industry Opportunities and Challenges Table 11. Gene-based Advanced Therapy Medical Product Industry Restraints Table 12. Global Gene-based Advanced Therapy Medical Product Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Gene-based Advanced Therapy Medical Product Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Gene-based Advanced Therapy Medical Product Market Share by Region (2021-2026) Table 15. Global Gene-based Advanced Therapy Medical Product Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Gene-based Advanced Therapy Medical Product Market Share by Region (2027-2032) Table 17. Global Gene-based Advanced Therapy Medical Product Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Gene-based Advanced Therapy Medical Product Revenue Market Share by Players (2021-2026) Table 19. Global Gene-based Advanced Therapy Medical Product Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Gene-based Advanced Therapy Medical Product Key Players Headquarters & Area Served Table 21. Global Gene-based Advanced Therapy Medical Product Players, Product Type & Application Table 22. Global Gene-based Advanced Therapy Medical Product Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Gene-based Advanced Therapy Medical Product by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Gene-based Advanced Therapy Medical Product Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Gene-based Advanced Therapy Medical Product Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Gene-based Advanced Therapy Medical Product Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Gene-based Advanced Therapy Medical Product Revenue Market Share by Type (2021-2026) Table 29. Global Gene-based Advanced Therapy Medical Product Revenue Market Share by Type (2027-2032) Table 30. Global Gene-based Advanced Therapy Medical Product Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Gene-based Advanced Therapy Medical Product Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Gene-based Advanced Therapy Medical Product Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Gene-based Advanced Therapy Medical Product Revenue Market Share by Application (2021-2026) Table 34. Global Gene-based Advanced Therapy Medical Product Revenue Market Share by Application (2027-2032) Table 35. Novartis Company Information Table 36. Novartis Business Overview Table 37. Novartis Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Novartis Gene-based Advanced Therapy Medical Product Product Portfolio Table 39. Novartis Recent Development Table 40. Amgen Company Information Table 41. Amgen Business Overview Table 42. Amgen Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Amgen Gene-based Advanced Therapy Medical Product Product Portfolio Table 44. Amgen Recent Development Table 45. Sunway Biotech Company Information Table 46. Sunway Biotech Business Overview Table 47. Sunway Biotech Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Sunway Biotech Gene-based Advanced Therapy Medical Product Product Portfolio Table 49. Sunway Biotech Recent Development Table 50. Spark Therapeutics Company Information Table 51. Spark Therapeutics Business Overview Table 52. Spark Therapeutics Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Spark Therapeutics Gene-based Advanced Therapy Medical Product Product Portfolio Table 54. Spark Therapeutics Recent Development Table 55. SIBIONO Company Information Table 56. SIBIONO Business Overview Table 57. SIBIONO Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. SIBIONO Gene-based Advanced Therapy Medical Product Product Portfolio Table 59. SIBIONO Recent Development Table 60. Sarepta Therapeutics Company Information Table 61. Sarepta Therapeutics Business Overview Table 62. Sarepta Therapeutics Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Sarepta Therapeutics Gene-based Advanced Therapy Medical Product Product Portfolio Table 64. Sarepta Therapeutics Recent Development Table 65. Orchard Therapeutics Company Information Table 66. Orchard Therapeutics Business Overview Table 67. Orchard Therapeutics Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Orchard Therapeutics Gene-based Advanced Therapy Medical Product Product Portfolio Table 69. Orchard Therapeutics Recent Development Table 70. Human Stem Cells Institute Company Information Table 71. Human Stem Cells Institute Business Overview Table 72. Human Stem Cells Institute Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Human Stem Cells Institute Gene-based Advanced Therapy Medical Product Product Portfolio Table 74. Human Stem Cells Institute Recent Development Table 75. Gilead Sciences Company Information Table 76. Gilead Sciences Business Overview Table 77. Gilead Sciences Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Gilead Sciences Gene-based Advanced Therapy Medical Product Product Portfolio Table 79. Gilead Sciences Recent Development Table 80. bluebird bio Company Information Table 81. bluebird bio Business Overview Table 82. bluebird bio Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. bluebird bio Gene-based Advanced Therapy Medical Product Product Portfolio Table 84. bluebird bio Recent Development Table 85. Biogen Company Information Table 86. Biogen Business Overview Table 87. Biogen Gene-based Advanced Therapy Medical Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Biogen Gene-based Advanced Therapy Medical Product Product Portfolio Table 89. Biogen Recent Development Table 90. AnGes Company Information Table 91. AnGes Business Overview Table 92. AnGes Gene-based Advanced Therapy Medical Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. AnGes Gene-based Advanced Therapy Medical Product Product Portfolio Table 94. AnGes Recent Development Table 95. Alnylam Pharmaceuticals Company Information Table 96. Alnylam Pharmaceuticals Business Overview Table 97. Alnylam Pharmaceuticals Gene-based Advanced Therapy Medical Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Alnylam Pharmaceuticals Gene-based Advanced Therapy Medical Product Product Portfolio Table 99. Alnylam Pharmaceuticals Recent Development Table 100. Akcea Therapeutics Company Information Table 101. Akcea Therapeutics Business Overview Table 102. Akcea Therapeutics Gene-based Advanced Therapy Medical Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Akcea Therapeutics Gene-based Advanced Therapy Medical Product Product Portfolio Table 104. Akcea Therapeutics Recent Development Table 105. North America Gene-based Advanced Therapy Medical Product Revenue by Type (2021-2026) & (US$ Million) Table 106. North America Gene-based Advanced Therapy Medical Product Revenue by Type (2027-2032) & (US$ Million) Table 107. North America Gene-based Advanced Therapy Medical Product Revenue by Application (2021-2026) & (US$ Million) Table 108. North America Gene-based Advanced Therapy Medical Product Revenue by Application (2027-2032) & (US$ Million) Table 109. North America Gene-based Advanced Therapy Medical Product Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. North America Gene-based Advanced Therapy Medical Product Revenue by Country (2021-2026) & (US$ Million) Table 111. North America Gene-based Advanced Therapy Medical Product Revenue by Country (US$ Million) & (2027-2032) Table 112. Europe Gene-based Advanced Therapy Medical Product Revenue by Type (2021-2026) & (US$ Million) Table 113. Europe Gene-based Advanced Therapy Medical Product Revenue by Type (2027-2032) & (US$ Million) Table 114. Europe Gene-based Advanced Therapy Medical Product Revenue by Application (2021-2026) & (US$ Million) Table 115. Europe Gene-based Advanced Therapy Medical Product Revenue by Application (2027-2032) & (US$ Million) Table 116. Europe Gene-based Advanced Therapy Medical Product Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. Europe Gene-based Advanced Therapy Medical Product Revenue by Country (2021-2026) & (US$ Million) Table 118. Europe Gene-based Advanced Therapy Medical Product Revenue by Country (US$ Million) & (2027-2032) Table 119. China Gene-based Advanced Therapy Medical Product Revenue by Type (2021-2026) & (US$ Million) Table 120. China Gene-based Advanced Therapy Medical Product Revenue by Type (2027-2032) & (US$ Million) Table 121. China Gene-based Advanced Therapy Medical Product Revenue by Application (2021-2026) & (US$ Million) Table 122. China Gene-based Advanced Therapy Medical Product Revenue by Application (2027-2032) & (US$ Million) Table 123. Asia Gene-based Advanced Therapy Medical Product Revenue by Type (2021-2026) & (US$ Million) Table 124. Asia Gene-based Advanced Therapy Medical Product Revenue by Type (2027-2032) & (US$ Million) Table 125. Asia Gene-based Advanced Therapy Medical Product Revenue by Application (2021-2026) & (US$ Million) Table 126. Asia Gene-based Advanced Therapy Medical Product Revenue by Application (2027-2032) & (US$ Million) Table 127. Asia Gene-based Advanced Therapy Medical Product Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Asia Gene-based Advanced Therapy Medical Product Revenue by Region (US$ Million) & (2021-2026) Table 129. Asia Gene-based Advanced Therapy Medical Product Revenue by Region (US$ Million) & (2027-2032) Table 130. SAMEA Gene-based Advanced Therapy Medical Product Revenue by Type (2021-2026) & (US$ Million) Table 131. SAMEA Gene-based Advanced Therapy Medical Product Revenue by Type (2027-2032) & (US$ Million) Table 132. SAMEA Gene-based Advanced Therapy Medical Product Revenue by Application (2021-2026) & (US$ Million) Table 133. SAMEA Gene-based Advanced Therapy Medical Product Revenue by Application (2027-2032) & (US$ Million) Table 134. SAMEA Gene-based Advanced Therapy Medical Product Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. SAMEA Gene-based Advanced Therapy Medical Product Revenue by Country (2021-2026) & (US$ Million) Table 136. SAMEA Gene-based Advanced Therapy Medical Product Revenue by Country (US$ Million) & (2027-2032) Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Gene-based Advanced Therapy Medical Product Image Figure 2. Global Gene-based Advanced Therapy Medical Product Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gene-based Advanced Therapy Medical Product Market Size Share 2021 VS 2025 VS 2032 Figure 4. Viral Gene Delivery System Image Figure 5. Non-viral Gene Delivery System Image Figure 6. Global Gene-based Advanced Therapy Medical Product Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Gene-based Advanced Therapy Medical Product Market Size Share 2021 VS 2025 VS 2032 Figure 8. Neurological Diseases Image Figure 9. Cancer Image Figure 10. Other Image Figure 11. Global Gene-based Advanced Therapy Medical Product Market Size (US$ Million) & (2021-2032) Figure 12. Global Gene-based Advanced Therapy Medical Product Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Gene-based Advanced Therapy Medical Product Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Gene-based Advanced Therapy Medical Product Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Gene-based Advanced Therapy Medical Product Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Gene-based Advanced Therapy Medical Product Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Gene-based Advanced Therapy Medical Product Revenue Market Share by Type (2021-2032) Figure 19. Global Gene-based Advanced Therapy Medical Product Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Gene-based Advanced Therapy Medical Product Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Gene-based Advanced Therapy Medical Product Revenue Market Share by Application (2021-2032) Figure 22. North America Gene-based Advanced Therapy Medical Product Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Gene-based Advanced Therapy Medical Product Revenue Share by Type (2021-2032) Figure 24. North America Gene-based Advanced Therapy Medical Product Revenue Share by Application (2021-2032) Figure 25. North America Gene-based Advanced Therapy Medical Product Revenue Share by Country (2021-2032) Figure 26. United States Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Gene-based Advanced Therapy Medical Product Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Gene-based Advanced Therapy Medical Product Revenue Share by Type (2021-2032) Figure 31. Europe Gene-based Advanced Therapy Medical Product Revenue Share by Application (2021-2032) Figure 32. Europe Gene-based Advanced Therapy Medical Product Revenue Share by Country (2021-2032) Figure 33. Germany Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Gene-based Advanced Therapy Medical Product Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Gene-based Advanced Therapy Medical Product Revenue Share by Type (2021-2032) Figure 43. China Gene-based Advanced Therapy Medical Product Revenue Share by Application (2021-2032) Figure 44. Asia Gene-based Advanced Therapy Medical Product Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Gene-based Advanced Therapy Medical Product Revenue Share by Type (2021-2032) Figure 46. Asia Gene-based Advanced Therapy Medical Product Revenue Share by Application (2021-2032) Figure 47. Asia Gene-based Advanced Therapy Medical Product Revenue Share by Region (2021-2032) Figure 48. Japan Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Gene-based Advanced Therapy Medical Product Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Gene-based Advanced Therapy Medical Product Revenue Share by Type (2021-2032) Figure 56. SAMEA Gene-based Advanced Therapy Medical Product Revenue Share by Application (2021-2032) Figure 57. SAMEA Gene-based Advanced Therapy Medical Product Revenue Share by Country (2021-2032) Figure 58. Brazil Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Gene-based Advanced Therapy Medical Product Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Viral Gene Delivery System
  • Non-viral Gene Delivery System
Applications
  • Neurological Diseases
  • Cancer
  • Other
Companies covered
  • Novartis
  • Amgen
  • Sunway Biotech
  • Spark Therapeutics
  • SIBIONO
  • Sarepta Therapeutics
  • Orchard Therapeutics
  • Human Stem Cells Institute
  • Gilead Sciences
  • bluebird bio
  • Biogen
  • AnGes
  • Alnylam Pharmaceuticals
  • Akcea Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Gene-based Advanced Therapy Medical Product Market by Type
  3. 1.2.1 Global Gene-based Advanced Therapy Medical Product Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Viral Gene Delivery System
  5. 1.2.3 Non-viral Gene Delivery System
  6. 1.3 Gene-based Advanced Therapy Medical Product Market by Application
  7. 1.3.1 Global Gene-based Advanced Therapy Medical Product Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Neurological Diseases
  9. 1.3.3 Cancer
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Gene-based Advanced Therapy Medical Product Market Dynamics
  1. 2.1 Gene-based Advanced Therapy Medical Product Industry Trends
  2. 2.2 Gene-based Advanced Therapy Medical Product Industry Drivers
  3. 2.3 Gene-based Advanced Therapy Medical Product Industry Opportunities and Challenges
  4. 2.4 Gene-based Advanced Therapy Medical Product Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Gene-based Advanced Therapy Medical Product Market Perspective (2021-2032)
  2. 3.2 Global Gene-based Advanced Therapy Medical Product Growth Trends by Region
  3. 3.2.1 Global Gene-based Advanced Therapy Medical Product Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Gene-based Advanced Therapy Medical Product Market Size by Region (2021-2026)
  5. 3.2.3 Global Gene-based Advanced Therapy Medical Product Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Gene-based Advanced Therapy Medical Product Revenue by Players
  2. 4.1.1 Global Gene-based Advanced Therapy Medical Product Revenue by Players (2021-2026)
  3. 4.1.2 Global Gene-based Advanced Therapy Medical Product Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Gene-based Advanced Therapy Medical Product Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Gene-based Advanced Therapy Medical Product Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Gene-based Advanced Therapy Medical Product Key Players Headquarters & Area Served
  7. 4.4 Global Gene-based Advanced Therapy Medical Product Players, Product Type & Application
  8. 4.5 Global Gene-based Advanced Therapy Medical Product Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Gene-based Advanced Therapy Medical Product Market CR5 and HHI
  11. 4.6.3 2025 Gene-based Advanced Therapy Medical Product Tier 1, Tier 2, and Tier 3
5 Gene-based Advanced Therapy Medical Product Market Size by Type
  1. 5.1 Global Gene-based Advanced Therapy Medical Product Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Gene-based Advanced Therapy Medical Product Revenue by Type (2021-2032)
  3. 5.3 Global Gene-based Advanced Therapy Medical Product Revenue Market Share by Type (2021-2032)
6 Gene-based Advanced Therapy Medical Product Market Size by Application
  1. 6.1 Global Gene-based Advanced Therapy Medical Product Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Gene-based Advanced Therapy Medical Product Revenue by Application (2021-2032)
  3. 6.3 Global Gene-based Advanced Therapy Medical Product Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Gene-based Advanced Therapy Medical Product Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Amgen
  8. 7.2.1 Amgen Company Information
  9. 7.2.2 Amgen Business Overview
  10. 7.2.3 Amgen Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Amgen Gene-based Advanced Therapy Medical Product Product Portfolio
  12. 7.2.5 Amgen Recent Developments
  13. 7.3 Sunway Biotech
  14. 7.3.1 Sunway Biotech Company Information
  15. 7.3.2 Sunway Biotech Business Overview
  16. 7.3.3 Sunway Biotech Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sunway Biotech Gene-based Advanced Therapy Medical Product Product Portfolio
  18. 7.3.5 Sunway Biotech Recent Developments
  19. 7.4 Spark Therapeutics
  20. 7.4.1 Spark Therapeutics Company Information
  21. 7.4.2 Spark Therapeutics Business Overview
  22. 7.4.3 Spark Therapeutics Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Spark Therapeutics Gene-based Advanced Therapy Medical Product Product Portfolio
  24. 7.4.5 Spark Therapeutics Recent Developments
  25. 7.5 SIBIONO
  26. 7.5.1 SIBIONO Company Information
  27. 7.5.2 SIBIONO Business Overview
  28. 7.5.3 SIBIONO Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  29. 7.5.4 SIBIONO Gene-based Advanced Therapy Medical Product Product Portfolio
  30. 7.5.5 SIBIONO Recent Developments
  31. 7.6 Sarepta Therapeutics
  32. 7.6.1 Sarepta Therapeutics Company Information
  33. 7.6.2 Sarepta Therapeutics Business Overview
  34. 7.6.3 Sarepta Therapeutics Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Sarepta Therapeutics Gene-based Advanced Therapy Medical Product Product Portfolio
  36. 7.6.5 Sarepta Therapeutics Recent Developments
  37. 7.7 Orchard Therapeutics
  38. 7.7.1 Orchard Therapeutics Company Information
  39. 7.7.2 Orchard Therapeutics Business Overview
  40. 7.7.3 Orchard Therapeutics Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Orchard Therapeutics Gene-based Advanced Therapy Medical Product Product Portfolio
  42. 7.7.5 Orchard Therapeutics Recent Developments
  43. 7.8 Human Stem Cells Institute
  44. 7.8.1 Human Stem Cells Institute Company Information
  45. 7.8.2 Human Stem Cells Institute Business Overview
  46. 7.8.3 Human Stem Cells Institute Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Human Stem Cells Institute Gene-based Advanced Therapy Medical Product Product Portfolio
  48. 7.8.5 Human Stem Cells Institute Recent Developments
  49. 7.9 Gilead Sciences
  50. 7.9.1 Gilead Sciences Company Information
  51. 7.9.2 Gilead Sciences Business Overview
  52. 7.9.3 Gilead Sciences Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Gilead Sciences Gene-based Advanced Therapy Medical Product Product Portfolio
  54. 7.9.5 Gilead Sciences Recent Developments
  55. 7.10 bluebird bio
  56. 7.10.1 bluebird bio Company Information
  57. 7.10.2 bluebird bio Business Overview
  58. 7.10.3 bluebird bio Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  59. 7.10.4 bluebird bio Gene-based Advanced Therapy Medical Product Product Portfolio
  60. 7.10.5 bluebird bio Recent Developments
  61. 7.11 Biogen
  62. 7.11.1 Biogen Company Information
  63. 7.11.2 Biogen Business Overview
  64. 7.11.3 Biogen Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Biogen Gene-based Advanced Therapy Medical Product Product Portfolio
  66. 7.11.5 Biogen Recent Developments
  67. 7.12 AnGes
  68. 7.12.1 AnGes Company Information
  69. 7.12.2 AnGes Business Overview
  70. 7.12.3 AnGes Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  71. 7.12.4 AnGes Gene-based Advanced Therapy Medical Product Product Portfolio
  72. 7.12.5 AnGes Recent Developments
  73. 7.13 Alnylam Pharmaceuticals
  74. 7.13.1 Alnylam Pharmaceuticals Company Information
  75. 7.13.2 Alnylam Pharmaceuticals Business Overview
  76. 7.13.3 Alnylam Pharmaceuticals Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Alnylam Pharmaceuticals Gene-based Advanced Therapy Medical Product Product Portfolio
  78. 7.13.5 Alnylam Pharmaceuticals Recent Developments
  79. 7.14 Akcea Therapeutics
  80. 7.14.1 Akcea Therapeutics Company Information
  81. 7.14.2 Akcea Therapeutics Business Overview
  82. 7.14.3 Akcea Therapeutics Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Akcea Therapeutics Gene-based Advanced Therapy Medical Product Product Portfolio
  84. 7.14.5 Akcea Therapeutics Recent Developments
8 North America
  1. 8.1 North America Gene-based Advanced Therapy Medical Product Revenue (2021-2032)
  2. 8.2 North America Gene-based Advanced Therapy Medical Product Revenue by Type (2021-2032)
  3. 8.2.1 North America Gene-based Advanced Therapy Medical Product Revenue by Type (2021-2026)
  4. 8.2.2 North America Gene-based Advanced Therapy Medical Product Revenue by Type (2027-2032)
  5. 8.3 North America Gene-based Advanced Therapy Medical Product Revenue Share by Type (2021-2032)
  6. 8.4 North America Gene-based Advanced Therapy Medical Product Revenue by Application (2021-2032)
  7. 8.4.1 North America Gene-based Advanced Therapy Medical Product Revenue by Application (2021-2026)
  8. 8.4.2 North America Gene-based Advanced Therapy Medical Product Revenue by Application (2027-2032)
  9. 8.5 North America Gene-based Advanced Therapy Medical Product Revenue Share by Application (2021-2032)
  10. 8.6 North America Gene-based Advanced Therapy Medical Product Revenue by Country
  11. 8.6.1 North America Gene-based Advanced Therapy Medical Product Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Gene-based Advanced Therapy Medical Product Revenue by Country (2021-2026)
  13. 8.6.3 North America Gene-based Advanced Therapy Medical Product Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Gene-based Advanced Therapy Medical Product Revenue (2021-2032)
  2. 9.2 Europe Gene-based Advanced Therapy Medical Product Revenue by Type (2021-2032)
  3. 9.2.1 Europe Gene-based Advanced Therapy Medical Product Revenue by Type (2021-2026)
  4. 9.2.2 Europe Gene-based Advanced Therapy Medical Product Revenue by Type (2027-2032)
  5. 9.3 Europe Gene-based Advanced Therapy Medical Product Revenue Share by Type (2021-2032)
  6. 9.4 Europe Gene-based Advanced Therapy Medical Product Revenue by Application (2021-2032)
  7. 9.4.1 Europe Gene-based Advanced Therapy Medical Product Revenue by Application (2021-2026)
  8. 9.4.2 Europe Gene-based Advanced Therapy Medical Product Revenue by Application (2027-2032)
  9. 9.5 Europe Gene-based Advanced Therapy Medical Product Revenue Share by Application (2021-2032)
  10. 9.6 Europe Gene-based Advanced Therapy Medical Product Revenue by Country
  11. 9.6.1 Europe Gene-based Advanced Therapy Medical Product Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Gene-based Advanced Therapy Medical Product Revenue by Country (2021-2026)
  13. 9.6.3 Europe Gene-based Advanced Therapy Medical Product Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Gene-based Advanced Therapy Medical Product Revenue (2021-2032)
  2. 10.2 China Gene-based Advanced Therapy Medical Product Revenue by Type (2021-2032)
  3. 10.2.1 China Gene-based Advanced Therapy Medical Product Revenue by Type (2021-2026)
  4. 10.2.2 China Gene-based Advanced Therapy Medical Product Revenue by Type (2027-2032)
  5. 10.3 China Gene-based Advanced Therapy Medical Product Revenue Share by Type (2021-2032)
  6. 10.4 China Gene-based Advanced Therapy Medical Product Revenue by Application (2021-2032)
  7. 10.4.1 China Gene-based Advanced Therapy Medical Product Revenue by Application (2021-2026)
  8. 10.4.2 China Gene-based Advanced Therapy Medical Product Revenue by Application (2027-2032)
  9. 10.5 China Gene-based Advanced Therapy Medical Product Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Gene-based Advanced Therapy Medical Product Revenue (2021-2032)
  2. 11.2 Asia Gene-based Advanced Therapy Medical Product Revenue by Type (2021-2032)
  3. 11.2.1 Asia Gene-based Advanced Therapy Medical Product Revenue by Type (2021-2026)
  4. 11.2.2 Asia Gene-based Advanced Therapy Medical Product Revenue by Type (2027-2032)
  5. 11.3 Asia Gene-based Advanced Therapy Medical Product Revenue Share by Type (2021-2032)
  6. 11.4 Asia Gene-based Advanced Therapy Medical Product Revenue by Application (2021-2032)
  7. 11.4.1 Asia Gene-based Advanced Therapy Medical Product Revenue by Application (2021-2026)
  8. 11.4.2 Asia Gene-based Advanced Therapy Medical Product Revenue by Application (2027-2032)
  9. 11.5 Asia Gene-based Advanced Therapy Medical Product Revenue Share by Application (2021-2032)
  10. 11.6 Asia Gene-based Advanced Therapy Medical Product Revenue by Country
  11. 11.6.1 Asia Gene-based Advanced Therapy Medical Product Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Gene-based Advanced Therapy Medical Product Revenue by Country (2021-2026)
  13. 11.6.3 Asia Gene-based Advanced Therapy Medical Product Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Gene-based Advanced Therapy Medical Product Revenue (2021-2032)
  2. 12.2 SAMEA Gene-based Advanced Therapy Medical Product Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Gene-based Advanced Therapy Medical Product Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Gene-based Advanced Therapy Medical Product Revenue by Type (2027-2032)
  5. 12.3 SAMEA Gene-based Advanced Therapy Medical Product Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Gene-based Advanced Therapy Medical Product Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Gene-based Advanced Therapy Medical Product Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Gene-based Advanced Therapy Medical Product Revenue by Application (2027-2032)
  9. 12.5 SAMEA Gene-based Advanced Therapy Medical Product Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Gene-based Advanced Therapy Medical Product Revenue by Country
  11. 12.6.1 SAMEA Gene-based Advanced Therapy Medical Product Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Gene-based Advanced Therapy Medical Product Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Gene-based Advanced Therapy Medical Product Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst